Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Faslodex Maintenance in HER2- Metastatic Breast Cancer
NCT02383030Phase 3Unknown
- Sponsor
- Consorzio Oncotech
- Start
- Nov 2015
- Primary completion
- Sep 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of fulvestrant in breast cancer, sponsored by Consorzio Oncotech. Status: unknown.
02
Drugs
fulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02383030.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02383030.